Lumigan 0.01%
Lumigan 0.01% Uses, Dosage, Side Effects, Food Interaction and all others data.
Lumigan 0.01% is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Lumigan 0.01% reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Lumigan 0.01% is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Lumigan 0.01% may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.
High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Lumigan 0.01% rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes.
Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.
| Trade Name | Lumigan 0.01% |
| Generic | Bimatoprost |
| Bimatoprost Other Names | Bimatoprost, Bimatoprostum |
| Type | |
| Formula | C25H37NO4 |
| Weight | Average: 415.5656 Monoisotopic: 415.272258677 |
| Protein binding | Bimatoprost is about 88%-90% bound to plasma proteins. |
| Groups | Approved, Investigational |
| Therapeutic Class | Drugs for miotics and glaucoma |
| Manufacturer | |
| Available Country | Singapore |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Lumigan 0.01% is used for Ocular hypertension, Open-angle glaucoma
Lumigan 0.01% is also used to associated treatment for these conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP), Ocular Hypertension
How Lumigan 0.01% works
Lumigan 0.01% imitates the effects of prostamides, specifically prostaglandin F2α. Lumigan 0.01% mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Lumigan 0.01% does not affect aqueous humor production.
Dosage
Lumigan 0.01% dosage
Adult: Instill 1 drop into affected eye(s) once every night.
Side Effects
Common side effects are: Burning/stinging/irritation/ redness/discomfort of the eye, Feeling as if something is in your eye, Dry eyes, Watering eyes, Temporary unstable vision, Increased sensitivity to light, Dizziness.
Toxicity
No information is available at this time regarding bimatoprost overdose in humans. Provide supportive symptomatic treatment if an overdose occurs.
Precaution
May increase pigmentation of the iris, periorbital tissue and eyelashes. Active intraocular inflammation. Safety and efficacy have not been evaluated in the treatment of inflammatory, neovascular or angle closure glaucoma. Ensure at least an interval of 5 minutes between admin of ophthalmic preparations. Contact lenses should be removed prior to admin. Pregnancy, lactation.
Interaction
There is not known drug interactions and none well documented.
Food Interaction
No interactions found.Volume of Distribution
The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.
Elimination Route
This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Lumigan 0.01% was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing.
One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Lumigan 0.01% effects may last up to 24 hours.
Half Life
The elimination half-life of bimatoprost is approximately 45 minutes.
Clearance
The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.
Elimination Route
One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.
Pregnancy & Breastfeeding use
Pregnancy Category C. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.
Contraindication
Known hypersensitivity.
Acute Overdose
Treatment is symptomatic.
Storage Condition
Store at 2-25° C.
Innovators Monograph
You find simplified version here Lumigan 0.01%
Lumigan 0.01% contains Bimatoprost see full prescribing information from innovator Lumigan 0.01% Monograph, Lumigan 0.01% MSDS, Lumigan 0.01% FDA label
